Phase II Success Positions Ra For Potential Blockbuster Opportunity In Myasthenia Gravis
Executive Summary
Ra hopes to launch a Phase III program for zilucoplan next year, with a goal of bringing an alternative therapy for MG patients into competition with Alexion’s Soliris.
You may also be interested in...
Argenx Builds Presence As Efgartigimod Positive In Pivotal Myasthenia Study
The European biotech argenx has reported positive top-line results for its FcRn antagonist efgartigimod in generalized myasthenia gravis in the Phase III ADAPT study, and is planning to market the product itself in the US, Japan and major EU countries.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
Finance Watch: Amarin Raises Cash To Boost Vascepa Marketing Under Soon-To-Be Expanded Label
Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.
Need a specific report? 1000+ reports available
Buy Reports